Spruce Biosciences Prices Equity Offering to Raise Capital

Spruce Biosciences ( (SPRB) ) just unveiled an update.

On April 20, 2026, Spruce Biosciences entered into an underwriting agreement with a syndicate led by Leerink Partners, Guggenheim Securities and Oppenheimer to sell 1,150,000 shares of common stock at $50.00 per share and 50,000 pre-funded warrants at $49.99 each. All securities are being sold by the company under an effective shelf registration, and the pre-funded warrants are immediately exercisable subject to ownership caps designed to limit any holder’s beneficial stake in the company.

The underwriters exercised in full a 30-day option on April 21, 2026 to purchase an additional 180,000 shares at the public offering price, bringing expected gross proceeds to approximately $69 million before fees, with closing anticipated on April 22, 2026. This equity raise meaningfully bolsters Spruce’s balance sheet as it advances late-stage neurological programs, though it also dilutes existing shareholders while broadening the company’s institutional investor base.

The most recent analyst rating on (SPRB) stock is a Buy with a $283.00 price target. To see the full list of analyst forecasts on Spruce Biosciences stock, see the SPRB Stock Forecast page.

Spark’s Take on SPRB Stock

According to Spark, TipRanks’ AI Analyst, SPRB is a Neutral.

The score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn) and bearish technical positioning (below key moving averages). Corporate events provide a modest offset via encouraging TA-ERT clinical/regulatory updates and improved financing flexibility, while valuation signals are limited due to negative earnings and no dividend data.

To see Spark’s full report on SPRB stock, click here.

More about Spruce Biosciences

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company listed on Nasdaq under the ticker SPRB. It focuses on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, positioning the company in the specialty neuroscience and rare-disease segment of the biopharma industry.

The company’s pipeline and strategy target conditions where existing treatment options are limited, aiming to capture value in high-need patient populations. This focus places Spruce among smaller clinical-stage players seeking capital to advance expensive late-stage development and potential commercialization activities.

Average Trading Volume: 56,066

Technical Sentiment Signal: Hold

Current Market Cap: $95.9M

For an in-depth examination of SPRB stock, go to TipRanks’ Overview page.